FDA approves Signifor LAR to treat Acromegaly where surgery is not an option- Novartis

Novartis announced that the FDA has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with Acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. The approval of Signifor LAR, a next-generation somatostatin analog (SSA), helps address a critical unmet need among the Acromegaly patient population. Signifor LAR has been studied and found effective in both medically na�ve patients with Acromegaly who have had prior surgery or for whom surgery was not an option, as well as patients whose disease is not fully controlled on first generation SSAs.